Shanshan Qi, Lan Zhang, Haochen Wu, Xiaoyu An, Weibin Tan*, Xiaoyan Fu*, Meng Qiao, Qian Shi, WenQing Yang
*Taicang Blood Center, Taicang, Suzhou, P.R. China
As immuno-oncology continues to dominate preclinical cancer research, improved immunocompetent and humanised mouse models are needed. This is particularly true for bispecific antibody assessment, where there are many potential new therapies in preclinical and clinical development.
CrownBio has developed a panel of PBMC-humanised models which provide a fast, reliable, and cost effective platform for the preclinical efficacy testing of bispecific antibodies.
The model platform also has a range of other immuno-oncology applications including the testing of targeted cancer immunotherapies.